MedTrace Logo

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

NCT00027911 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-02-15

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective in treating soft tissue sarcoma.

PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with sargramostim in treating patients who have stage II, stage III, or stage IV soft tissue sarcoma.

Conditions

  • Sarcoma

Interventions

BIOLOGICAL

NY-ESO-1 peptide vaccine

BIOLOGICAL

sargramostim

Sponsors & Collaborators

Principal Investigators

  • Kyriakos P. Papadopoulos, MD · Herbert Irving Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027911 on ClinicalTrials.gov